top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Lisa Rojkjaer Biography and Net Worth

Insider of Viracta Therapeutics

Dr. Lisa Rojkjaer joined Viracta Therapeutics in May 2020 as Chief Medical Officer. Previously, Dr. Rojkjaer served as the Chief Medical Officer at Nordic Nanovector from November 2016 to April 2020. Prior to this, Dr. Rojkjaer held several senior management positions in biotech and global pharmaceutical companies. She was the Global Clinical Program Head for AML at Novartis Oncology from October 2013 to November 2016. Her previous roles also included Chief Medical Officer at Molecular Partners, and Vice President, Head of Clinical Development at MorphoSys AG. Dr. Rojkjaer received her medical degree from the University of Toronto, where she also completed her internal medicine and hematology training.

What is Lisa Rojkjaer's net worth?: The estimated net worth of Lisa Rojkjaer is at least $40,768.16 as of February 27th, 2023. Dr. Rojkjaer owns 48,087 shares of Viracta Therapeutics stock worth more than $40,768 as of April 24th. This net worth estimate does not reflect any other assets that Dr. Rojkjaer may own. Learn More about Lisa Rojkjaer's net worth.
How do I contact Lisa Rojkjaer?: The corporate mailing address for Dr. Rojkjaer and other Viracta Therapeutics executives is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. Viracta Therapeutics can also be reached via phone at (858) 400-8470 and via email at [email protected]. Learn More on Lisa Rojkjaer's contact information.
Has Lisa Rojkjaer been buying or selling shares of Viracta Therapeutics?: Lisa Rojkjaer has not been actively trading shares of Viracta Therapeutics over the course of the past ninety days. Most recently, Lisa Rojkjaer sold 2,156 shares of the business's stock in a transaction on Monday, February 27th. The shares were sold at an average price of $1.68, for a transaction totalling $3,622.08. Following the completion of the sale, the insider now directly owns 48,087 shares of the company's stock, valued at $80,786.16. Learn More on Lisa Rojkjaer's trading history.
Who are Viracta Therapeutics' active insiders?: Viracta Therapeutics' insider roster includes Daniel Chevallard (CFO), Lisa Rojkjaer (Insider), and Ivor Royston (CEO). Learn More on Viracta Therapeutics' active insiders.
Are insiders buying or selling shares of Viracta Therapeutics?: In the last year, Viracta Therapeutics insiders bought shares 1 times. They purchased a total of 52,094 shares worth more than $25,526.06. In the last year, insiders at the sold shares 4 times. They sold a total of 14,272 shares worth more than $14,599.75. The most recent insider tranaction occured on February, 27th when CFO Daniel R Chevallard sold 3,405 shares worth more than $2,485.65. Insiders at Viracta Therapeutics own 7.4% of the company. Learn More about insider trades at Viracta Therapeutics.
Information on this page was last updated on 2/27/2024.

Lisa Rojkjaer Insider Trading History at Viracta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/27/2023	Sell	2,156	$1.68	$3,622.08	48,087
11/28/2022	Sell	2,116	$2.72	$5,755.52	46,116
8/26/2022	Sell	2,190	$4.01	$8,781.90	44,105
5/26/2022	Sell	2,154	$1.90	$4,092.60	42,168
2/28/2022	Sell	2,395	$2.78	$6,658.10
11/29/2021	Sell	2,591	$4.82	$12,488.62
11/26/2021	Sell	1,950	$4.80	$9,360.00

Lisa Rojkjaer Buying and Selling Activity at Viracta Therapeutics

Viracta Therapeutics Company Overview

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

Today's Range

Now: $0.85

$0.76

$0.91

50 Day Range

MA: $0.92

$0.62

$1.17

2 Week Range

Now: $0.85

$0.43

$2.38

Volume

83,968 shs

Average Volume

111,161 shs

Market Capitalization

$33.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93